China’s 15th Five-Year Plan prioritizes rare disease drugs, but payment gap blocks patient access
China’s 15th Five-Year Plan for the pharmaceutical industry, issued by ten ministries, prioritizes cell and gene therapies for rare diseases like hemophilia and ALS. However, industry experts at the 2026 Zhangjiang Pharma Conference in Shanghai highlighted a critical payment bottleneck: in 2025, personal payments accounted for 893 billion yuan of the 1.95 trillion yuan innovative drug market, while commercial insurance covered only 15.2 billion yuan. Experts call for multi-tiered payment systems, special funds, and legislation to bridge the “last mile” to patients.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China's rare disease drug payment puzzle: How to bridge the 'last mile'?
A new ten-agency plan from China's Ministry of Industry and Information Technology outlines priorities for rare disease drug innovation, including cell and gene therapies. However, industry experts at recent conferences in Shanghai highlighted a critical bottleneck: payment. Despite a 2025 market size of 1.95 trillion yuan for innovative drugs, personal payments account for 893 billion yuan, indicating heavy patient burden. Experts like Zhang Xiaodong of Meditrust Health argue that AI can improve payment capacity and market assessment. The article details challenges including high gene therapy costs (up to millions of dollars per patient), low commercial insurance uptake, and fragmented government policies. Proposed solutions include rare disease legislation, a national special fund, multi-tiered insurance combining basic medical insurance, commercial insurance, and charity, as well as expanding risk pools through products like student insurance. Industry leaders from AstraZeneca and北海康成 (北海康成) call for better multi-level guarantee mechanisms and local pilot programs in Shanghai to create a replicable model.
Read sourceChina's Rare Disease Drug Payment Puzzle: How to Bridge the 'Last Mile' to Patients
A 21st Century Business Herald article examines the critical challenge of paying for innovative rare disease drugs in China, following the release of the '15th Five-Year Plan' for the pharmaceutical industry. The plan prioritizes R&D for cell and gene therapies for conditions like hemophilia and ALS. However, industry experts at the 2026 Zhangjiang Pharma Conference highlighted that while China's innovative drug market is large (estimated at 1.95 trillion yuan in 2025), personal payments still account for 893 billion yuan, placing a heavy burden on patients. Magnesium Health CEO Zhang Xiaodong called for a more diversified payment system involving basic medical insurance, commercial health insurance, and patient programs. Rare disease drugs face unique hurdles due to high costs (up to millions of dollars per treatment) and small patient populations. Experts from AstraZeneca,北海康成, and Shanghai Guotou Fund discussed the need for special funds, improved commercial insurance products like 'Huiminbao', and better coordination between government departments. The article notes that AI could help payers better assess risk and willingness to pay, potentially expanding the domestic market for Chinese innovative drugs.
China's rare disease drug payment puzzle: How to bridge the 'last mile' for innovative therapies
This article analyzes the critical challenge of payment for rare disease innovative drugs in China, framed as the 'last mile' connecting innovation to patient access. It reports that China's 15th Five-Year Plan for the pharmaceutical industry prioritizes rare disease therapies including cell and gene treatments. Despite China's growing biopharma market (6.55 trillion yuan in 2025) and record out-licensing deals ($1,300 billion in 2025), the payment system remains fragmented. Data from the 2026 White Paper shows that in 2025, basic medical insurance covered 905 billion yuan of innovative drug sales, personal payments accounted for 893 billion yuan, and commercial health insurance only 152 billion yuan, indicating heavy patient burden. Experts including Zhang Xiaodong (CEO of Meditrust Health) and Kang Qi (Shanghai Health Development Research Center) call for a multi-tier payment system combining basic insurance, special funds, commercial insurance, and charity. The article highlights that rare disease treatments face unique challenges: high unit costs (gene therapies up to millions of dollars), small patient populations, and difficulty in commercial insurance underwriting. Industry leaders from AstraZeneca,北海康成, and investment funds urge for local legislation, special funds, and better coordination across government departments. The article concludes that AI could improve risk assessment and payment capacity, and that China's rare disease ecosystem needs to move from R&D strength to sustainable commercialization.
Read sourceShow 2 older updatesHide older updates
China's rare disease drug payment puzzle: How to bridge the 'last mile'?
This article analyzes the persistent challenge of paying for innovative rare disease drugs in China, despite significant progress in R&D and regulatory approvals. It cites the '15th Five-Year Plan' for the pharmaceutical industry, which prioritizes gene and cell therapies for rare diseases. Industry leaders, including Zhang Xiaodong of Meditrust Health, argue that China's domestic market has huge potential but is constrained by a payment system heavily reliant on basic medical insurance and patient out-of-pocket costs. Data from the '2026 China Innovative Drug Multi-Payment White Paper' shows that in 2025, out of a 195 billion yuan market, basic insurance covered 90.5 billion, patients paid 89.3 billion, and commercial insurance only 15.2 billion. Experts call for a multi-tiered payment system involving commercial insurance, charitable funds, and government special funds. The article highlights the high cost of gene therapies (up to millions of dollars per patient) and the difficulty of integrating rare disease coverage into existing insurance models like 'Huiminbao'. It concludes that legislative action and cross-departmental coordination are needed to build a sustainable ecosystem.
Read sourceChina's Rare Disease Drug Payment Puzzle: How to Bridge the 'Last Mile' to Patients
A 21st Century Business Herald analysis examines the critical challenge of paying for rare disease drugs in China, following the release of the '15th Five-Year Plan' for the pharmaceutical industry. The plan prioritizes cell and gene therapies for conditions like hemophilia and ALS. Despite China's growing biotech market (6.55 trillion yuan in 2025) and record out-licensing deals, patient access is hindered by high costs. The 2026 China Innovative Drug Multi-Payment White Paper shows that in 2025, of the 195 billion yuan market, basic medical insurance covered 90.5 billion, personal payments were 89.3 billion, and commercial insurance only 15.2 billion. Experts like Zhang Xiaodong (MediTrust Health) call for a multi-payer system involving insurance, commercial health plans, and charity funds. Industry leaders from AstraZeneca,北海康成, and Shanghai Guotou Fund highlight hurdles such as high gene therapy costs (up to millions of dollars), limited commercial insurance coverage, and the need for dedicated rare disease funds and legislation. AI is proposed to improve risk assessment and payment capacity. The article concludes that solving the payment issue is essential to realizing the full potential of China's domestic market for innovative drugs.
Read source